Holen Sie sich die Stockscreener-App
28.80
1.40%
-0.41
Handel nachbörslich:
27.43
-1.37
-4.76%
Schlusskurs vom Vortag:
$29.21
Offen:
$29.04
24-Stunden-Volumen:
1.20M
Relative Volume:
1.03
Marktkapitalisierung:
$1.96B
Einnahmen:
$2.74B
Nettoeinkommen (Verlust:
$-441.40M
KGV:
-4.4037
EPS:
-6.54
Netto-Cashflow:
$13.00M
1W Leistung:
-1.74%
1M Leistung:
-14.40%
6M Leistung:
+21.83%
1J Leistung:
-30.55%
1-Tages-Spanne:
$27.48
$29.40
1-Wochen-Bereich:
$27.48
$30.50
52-Wochen-Spanne:
$19.50
$43.92
Quidelortho Corporation Stock (QDEL) Company Profile
Firmenname
Quidelortho Corporation
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
28.80 | 1.98B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
113.59 | 195.24B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
363.70 | 138.08B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.08 | 130.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
73.47 | 110.11B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 44.71B | 5.88B | 1.34B | 799.60M | 2.3489 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corporation Aktie (QDEL) Neueste Nachrichten
QuidelOrtho (QDEL) Aims for Improved Margins and Strong Cash Flo - GuruFocus
QuidelOrtho Q4 2025 slides: Revenue beats expectations despite 27% EPS drop - Investing.com
QuidelOrtho Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: QuidelOrtho Q4 2025 misses EPS, stock dips - Investing.com
Earnings call transcript: QuidelOrtho Q4 2025 misses EPS, stock dips By Investing.com - Investing.com UK
QDEL Projects Significant Revenue Growth by FY26 - GuruFocus
QuidelOrtho (QDEL) Sees Mixed Growth Across Business Segments - GuruFocus
QuidelOrtho (QDEL) Exceeds Q4 Revenue Expectations with Diversif - GuruFocus
QuidelOrtho (QDEL) Projects Steady Covid-19 Revenue Through FY25 - GuruFocus
QuidelOrtho (QDEL) Projects Strong Financial Performance for FY2 - GuruFocus
QuidelOrtho (QDEL) CFO Announces Retirement Plans - GuruFocus
QuidelOrtho (QDEL) Projects FY26 Tax Rate at 24% - GuruFocus
QuidelOrtho Q4 2025 Earnings: Revenue & Profit Beat, 2026 Outlook CautiousNews and Statistics - IndexBox
QuidelOrtho Q4 Earnings Fall, Revenue Rises; Issues Guidance - marketscreener.com
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
QuidelOrtho (NASDAQ:QDEL) Exceeds Q4 CY2025 Expectations - Finviz
QuidelOrtho Q4 results beat on both lines, but issues weak 2026 EPS guidance - MSN
QuidelOrtho: Q4 Earnings Snapshot - kare11.com
QuidelOrtho: Fourth Quarter Financial Highlights - Bitget
QuidelOrtho (NASDAQ:QDEL) Issues Earnings Results - MarketBeat
Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q4 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.42 - marketscreener.com
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results - PR Newswire
QuidelOrtho (NASDAQ:QDEL) Surpasses Projections for Q4 CY2025 - Bitget
Weekly Recap: Is QuidelOrtho Corporation a turnaround storyJuly 2025 Snapshot & Weekly High Momentum Picks - baoquankhu1.vn
Why is QuidelOrtho Corporation stock going downJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Will QuidelOrtho Corporation benefit from rising consumer demandVolume Spike & Technical Buy Zone Confirmations - mfd.ru
Earnings To Watch: QuidelOrtho (QDEL) Reports Q4 Results Tomorrow - Yahoo Finance
Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline - Eastern Progress
Earnings preview: QuidelOrtho (QDEL) Q4 earnings expected to decline - MSN
Aug Opening: What are the future prospects of iSpecimen Inc2025 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
QuidelOrtho director Matthew W. Strobeck to step down after annual meeting - Investing.com Nigeria
QuidelOrtho Announces Board Director Matthew Strobeck’s Departure - TipRanks
QuidelOrtho director Matthew W. Strobeck to step down after annual meeting By Investing.com - Investing.com South Africa
Does QuidelOrtho Corporation offer margin of safety2025 Momentum Check & Fast Gaining Stock Reports - baoquankhu1.vn
RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating - MSN
QuidelOrtho: EBIT Margins In Focus As We Approach Q4 Earnings Release (NASDAQ:QDEL) - Seeking Alpha
QuidelOrtho (QDEL) to Release Earnings on Wednesday - MarketBeat
QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Rating of "Hold" by Brokerages - MarketBeat
QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards - Barchart.com
Ballast Asset Management LP Has $2.36 Million Stock Holdings in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho Faces Profitability Pressures Yet Trades At Steep Valuation Discount - simplywall.st
Aug Final Week: Whats the fair value of NextEra Energy Inc Preferred Security stockEarnings Growth Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
Gagnon Securities LLC Grows Stock Holdings in QuidelOrtho Corporation $QDEL - MarketBeat
Is QuidelOrtho (QDEL) A Value Opportunity After Steep Multi‑Year Share Price Declines - simplywall.st
QuidelOrtho Corporation (QDEL) Investor Outlook: Analyzing a Potential 33.66% Upside in the Healthcare Sector - DirectorsTalk Interviews
3 Reasons to Sell QDEL and 1 Stock to Buy Instead - Finviz
3 Reasons QDEL is Risky and 1 Stock to Buy Instead - Finviz
Is QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story? - simplywall.st
QuidelOrtho (NASDAQ:QDEL) Shares Down 7.9%Time to Sell? - MarketBeat
QuidelOrtho (QDEL) Valuation Check After Steep Share Price Slide And Rising Financial Distress Concerns - simplywall.st
Strengthening the blood supply: Awareness, challenges and donor impact - Finviz
Finanzdaten der Quidelortho Corporation-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.61%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):